Skip to main content
Premium Trial:

Request an Annual Quote

Informax Releases Genomax 3.0

NEW YORK, Sept 18 – Bioinformatics company Informax of Rockville, Md., said Monday it had released version 3.0 of Genomax, a software package that includes modules for sequence analysis, gene expression analysis, and 3-dimensional protein structure.

The software, which is geared to help pharmaceutical and biotechnology companies to integrate vast amounts of data, is designed for a multi-user environment. The software employs Oracle relational databases as well as a Java-based graphical user interface.

Genomax users include DuPont, Genzyme, Pioneer Hi-Bred, the University of Tokyo, and Massachusetts Institute of Technology.

The company said it is currently working on integrating new modules into Genomax, including genomic viewing, protein-protein interaction, and SNP analysis.

Informax’s other main product is Vector NTI, a desktop application used for sequence analysis and visualization.

The company reported revenues of $3.2 million in first-quarter 2000, up from $1.6 million in the year ago period. Software sales accounted for $2.4 million of this year’s first-quarter sales.

The company is planning to raise $75 million in an initial public offering on the Nasdaq within the next month.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.